Last updated on July 2019

Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors


Brief description of study

Avelumab in combination with talazoparib will be investigated in patients with locally advanced or metastatic solid tumors with a BRCA or ATM defect.

Detailed Study Description

Avelumab is a human immunoglobulin (Ig)G1 monoclonal antibody (mAb) directed against programmed death ligand 1 (PD-L1). Avelumab selectively binds to PD-L1 and competitively blocks its interaction with programmed death receptor 1 (PD-1), thereby interfering with this key immune checkpoint inhibition pathway. Avelumab is currently being investigated as single agent and in combination with other anti cancer therapies in patients with locally advanced or metastatic solid tumors and various hematological malignancies.

Talazoparib is a potent, orally bioavailable poly (adenosine diphosphate [ADP] ribose) polymerase (PARP) inhibitor, which is cytotoxic to human cancer cell lines harboring gene mutations that compromise deoxyribonucleic acid (DNA) repair, an effect referred to as synthetic lethality, and by trapping PARP protein on DNA thereby preventing DNA repair, replication, and transcription.

Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors with a BReast CAncer susceptibility gene (BRCA)1, or BRCA2, or ataxia telangiectasia mutated (ATM) gene defect.

Clinical Study Identifier: NCT03565991

Find a site near you

Start Over

Stanford Cancer Center

Palo Alto, CA United States
  Connect »

Stanford Women's Cancer Center

Palo Alto, CA United States
  Connect »

Stanford Healthcare

Stanford, CA United States
  Connect »

Atlanta Cancer Care -Alpharetta

Alpharetta, GA United States
  Connect »

Ochsner Clinic Foundation

New Orleans, LA United States
  Connect »

Barnes-Jewish Hospital

Saint Louis, MO United States
  Connect »

Siteman Cancer Center - St.Peters

Saint Peters, MO United States
  Connect »

NYU Langone Medical Center

New York, NY United States
  Connect »

Memorial Hospital

New York, NY United States
  Connect »

The Ohio State University

Columbus, OH United States
  Connect »

Stephenson Cancer Center

Oklahoma City, OK United States
  Connect »

UPMC Hillman Cancer Center

Pittsburgh, PA United States
  Connect »

Tennessee Oncology, PLLC

Chattanooga, TN United States
  Connect »

Tennessee Oncology, PLLC

Cleveland, TN United States
  Connect »

Tennessee Oncology, PLLC

Dickson, TN United States
  Connect »

Tennessee Oncology, PLLC

Franklin, TN United States
  Connect »

Tennessee Oncology, PLLC

Gallatin, TN United States
  Connect »

Tennessee Oncology, PLLC

Hermitage, TN United States
  Connect »

Tennessee Oncology, PLLC

Lebanon, TN United States
  Connect »

Tennessee Oncology, PLLC

Murfreesboro, TN United States
  Connect »

Tennessee Oncology, PLLC

Nashville, TN United States
  Connect »

Tennessee Oncology, PLLC

Shelbyville, TN United States
  Connect »

Tennessee Oncology, PLLC

Smyrna, TN United States
  Connect »

The University of Texas

Houston, TX United States
  Connect »

UZ Brussel

Brussel, Belgium
  Connect »

Centre Jean Perrin

Clermont Ferrand, France
  Connect »

Harley Street at UCLH

London, United Kingdom
  Connect »

Pharmacy Department

London, United Kingdom
  Connect »

White Plains Hospital

White Plains, NY United States
  Connect »

Centre L on B rard

Lyon Cedex 08, France
  Connect »

NY Investigational Pharmacy

New York, NY United States
  Connect »

Rigshospitalet

Copenhagen, Denmark
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.